United States · Platforms & data · Morningstar

Novartis Raises Guidance After Trial Setbacks Hit Profit

Published by Morningstar · United States 11 h ago

Novartis raised its full-year earnings guidance, citing solid sales growth and productivity gains, even as recent clinical-trial setbacks hit the Swiss drugmaker's bottom line in…

Read the full article on Morningstar Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)

Also worth reading

Seeking Alpha

Novartis Raises Guidance After Trial Setbacks Hit Profit

Share

Also worth reading

Watsco GAAP EPS of $3.77 misses by $0.32, revenue of $2.22B beats by $10M

AI debt trouble could help Fed’s Warsh get his way with fewer rate hikes

Spotify Technology (NYSE:SPOT) Cut to "Moderate Buy" at Phillip Securities

Best Stocks Under $5

BTIG raises CareDx stock price target to $81 on revenue outlook

IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave